Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Fineline Cube Jul 6, 2026
Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company Deals

Stada Arzneimittel AG Partners with CR Sanjiu for Distribution in China

Fineline Cube Nov 24, 2023

Germany-based Stada Arzneimittel AG has announced a strategic distribution and promotion partnership with China’s state-owned...

Company Drug

C2 Pharma Secures C-DMF Approval for Pilocarpine Nitrate API

Fineline Cube Nov 24, 2023

Ireland-based C2 Pharma has announced the receipt of approval for a C-DMF (drug master file)...

Company Drug

SCG Cell Therapy’s SCG101 Receives Tacit Approval for Cholangiocarcinoma Clinical Trial in China

Fineline Cube Nov 23, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that SCG Cell Therapy Pte. Ltd’s...

Company Drug

Akeso Biopharma’s Cadonilimab Meets Primary Endpoint in Phase III Cervical Cancer Study

Fineline Cube Nov 23, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that its Phase III AK104-303 study for cadonilimab...

Company Drug

RemeGen’s Telitacicept Receives Full Approval for Systemic Lupus Erythematosus in China

Fineline Cube Nov 23, 2023

China-based pharmaceutical company RemeGen (HKG: 9995) has announced the conversion of conditional approval to complete...

Company Deals

Boehringer Ingelheim Acquires T3 Pharmaceuticals to Boost Immuno-Oncology Portfolio

Fineline Cube Nov 23, 2023

Germany’s Boehringer Ingelheim has announced the purchase of Switzerland-based biotechnology firm T3 Pharmaceuticals this week,...

Company Drug Legal / IP

Bayer Halts Late-Stage Trial for Asundexian After Underperformance

Fineline Cube Nov 23, 2023

Germany-headquartered Bayer (ETR: BAYN) announced the termination of a late-stage trial for its antithrombotic candidate...

Company Drug

Brii Biosciences’ BRII-179 Vaccine on Track for Breakthrough Therapy Designation in China

Fineline Cube Nov 23, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137),...

Company Deals

Venus Medtech Partners with Valgen Holding on DragonFly Valve System

Fineline Cube Nov 23, 2023

China-based Venus Medtech (Hangzhou) Inc., (HKG: 2500), has entered into a strategic partnership with Valgen...

Company Deals

Oculotronics Secures Pre-Series A Funding for Ophthalmic Surgical Robotics

Fineline Cube Nov 23, 2023

Oculotronics, a Guangzhou-based developer of ophthalmic surgical robots, has reportedly raised tens of millions of...

Company Drug

Sumitomo Pharma Receives Chinese Approval for Xenleta to Treat Pneumonia

Fineline Cube Nov 23, 2023

Japan-based Sumitomo Pharma Co., Ltd (OTCMKTS: DNPUF) has secured market approval in China for Xenleta...

Company Drug Medical Device

Gilead Announces Low-Carbon Bronchodilator Study for H1 2024

Fineline Cube Nov 23, 2023

Gilead Sciences Inc. (NASDAQ: GILD) has announced plans for a Phase III study in the...

Company Drug

Hunan Warrant Pharmaceutical’s ZG-001 Approved for Clinical Trial by NMPA

Fineline Cube Nov 22, 2023

Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving clinical...

Company Drug

VivaVision Biotech Inc. Receives FDA Approval for VVN461 Phase II Clinical Trial

Fineline Cube Nov 22, 2023

China’s VivaVision Biotech Inc. has announced that it has received approval from the US Food...

Company Drug

AnHeart Therapeutics and Innovent Biologics File Taletrectinib for Marketing Approval in China

Fineline Cube Nov 22, 2023

China’s Center for Drug Evaluation (CDE) has indicated on its website that taletrectinib, an ROS1/NTRK...

Company Deals

Genentech and NVIDIA Collaborate to Advance Drug Discovery with AI

Fineline Cube Nov 22, 2023

Genentech, a subsidiary of Swiss pharmaceutical giant Roche (SWX: ROG), has entered into a collaboration...

Company Deals

MSD to Acquire Caraway Therapeutics for USD 610 Million to Boost Neurodegenerative Disease Portfolio

Fineline Cube Nov 22, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an agreement to purchase Caraway Therapeutics,...

Company Drug

Janssen Submits Indication Extension Application to FDA for Rybrevant in NSCLC Treatment

Fineline Cube Nov 22, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has filed an indication extension...

Company Deals

EC Healthcare Partners with Jiangxi Rimag Group to Expand Medical Imaging Services

Fineline Cube Nov 22, 2023

China-based EC Healthcare (HKG: 2138) has entered into a partnership with Jiangxi Rimag Group Co.,...

Company Deals

Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments

Fineline Cube Nov 22, 2023

China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into...

Posts pagination

1 … 464 465 466 … 690

Recent updates

  • Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic
  • Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment
  • China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways
  • Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment
  • Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Others

China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways

Company Drug

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.